Ureteral stents for malignant extrinsic ureteral obstruction: outcomes and factors predicting stent failure.


Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 18 07 2018
accepted: 22 09 2018
pubmed: 10 10 2018
medline: 30 5 2019
entrez: 10 10 2018
Statut: ppublish

Résumé

This study investigated the clinical outcomes of stent placement for malignant extrinsic ureteral obstruction (MUO) and predictive factors for stent failure. We retrospectively analyzed clinical data for 91 patients with radiologically significant hydronephrosis due to MUO who underwent successful stent placement. In total, 132 ureters were stented for the decompression. Factors related to stent failure were analyzed with a Cox proportional hazards model. Stent failure occurred in 25 ureters in 20 patients. The median interval to failure was 63 days. The multivariate analysis showed that the significant predictors of stent failure were bladder invasion and severe hydronephrosis before the stent insertion. The patients were divided into three groups based on these two factors: low-risk (neither factor; 85 patients), intermediate-risk (one factor; 37), and high-risk (both factors; 10). The median stent failure-free survival rate at 3 months was 94.8% in the low-risk, 71.8% in the intermediate-risk and 55.6% in the high-risk group, respectively. Of the ureters with stent failure, there was successful re-replacement of internal stents in 3 low-risk, 6 intermediate-risk and no high-risk ureters. Replacement by nephrostomy was done in 2 low-risk, 5 intermediate-risk and 7 high-risk ureters. The patients considered at low-risk could be managed without stent failure by internal stenting. However, the patients at high-risk may require the consideration of nephrostomy or other alternatives as the initial treatment. Our stratification model may allow better risk stratification for patients with regard to ureteral stenting, helping to identify patients for whom ureteral stenting is indicated.

Sections du résumé

BACKGROUND BACKGROUND
This study investigated the clinical outcomes of stent placement for malignant extrinsic ureteral obstruction (MUO) and predictive factors for stent failure.
METHODS METHODS
We retrospectively analyzed clinical data for 91 patients with radiologically significant hydronephrosis due to MUO who underwent successful stent placement. In total, 132 ureters were stented for the decompression. Factors related to stent failure were analyzed with a Cox proportional hazards model.
RESULTS RESULTS
Stent failure occurred in 25 ureters in 20 patients. The median interval to failure was 63 days. The multivariate analysis showed that the significant predictors of stent failure were bladder invasion and severe hydronephrosis before the stent insertion. The patients were divided into three groups based on these two factors: low-risk (neither factor; 85 patients), intermediate-risk (one factor; 37), and high-risk (both factors; 10). The median stent failure-free survival rate at 3 months was 94.8% in the low-risk, 71.8% in the intermediate-risk and 55.6% in the high-risk group, respectively. Of the ureters with stent failure, there was successful re-replacement of internal stents in 3 low-risk, 6 intermediate-risk and no high-risk ureters. Replacement by nephrostomy was done in 2 low-risk, 5 intermediate-risk and 7 high-risk ureters.
CONCLUSION CONCLUSIONS
The patients considered at low-risk could be managed without stent failure by internal stenting. However, the patients at high-risk may require the consideration of nephrostomy or other alternatives as the initial treatment. Our stratification model may allow better risk stratification for patients with regard to ureteral stenting, helping to identify patients for whom ureteral stenting is indicated.

Identifiants

pubmed: 30298199
doi: 10.1007/s10147-018-1348-6
pii: 10.1007/s10147-018-1348-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

306-312

Références

Cancer. 1999 Feb 15;85(4):998-1003
pubmed: 10091780
J Urol. 2001 Nov;166(5):1746-9
pubmed: 11586215
J Urol. 2004 Aug;172(2):592-5
pubmed: 15247739
J Urol. 2005 Dec;174(6):2125-8
pubmed: 16280741
J Endourol. 2008 Feb;22(2):295-9
pubmed: 18294036
Urology. 2008 Aug;72(2):370-3
pubmed: 18336878
J Urol. 2008 Aug;180(2):618-21; discussion 621
pubmed: 18554655
J Urol. 2011 Feb;185(2):556-61
pubmed: 21168872
Int J Urol. 2011 May;18(5):379-82
pubmed: 21518020
Korean J Urol. 2013 May;54(5):316-21
pubmed: 23700497
Int Braz J Urol. 2014 Mar-Apr;40(2):225-31
pubmed: 24856490
BJU Int. 2016 Feb;117(2):266-71
pubmed: 25327474
J Urol. 2015 Apr;193(4):1092-100
pubmed: 25463984
Indian J Urol. 2015 Jan-Mar;31(1):8-14
pubmed: 25624569
Int J Urol. 2015 Jul;22(7):629-36
pubmed: 25950837
Hippokratia. 2014 Oct-Dec;18(4):292-7
pubmed: 26052193
PLoS One. 2015 Aug 12;10(8):e0135566
pubmed: 26267140
J Pain Symptom Manage. 2016 Feb;51(2):255-61
pubmed: 26497918
Oncol Lett. 2016 Jan;11(1):879-883
pubmed: 26870299
World J Nephrol. 2016 Mar 6;5(2):172-81
pubmed: 26981442
Asian J Urol. 2016 Jul;3(3):142-149
pubmed: 29264182
Cancer. 1987 Sep 15;60(6):1353-7
pubmed: 3621117

Auteurs

Hiroshi Matsuura (H)

Department of Urology, Mie Prefectural General Medical Center, 5450-132 Hinaga, Yokkaichi, Mie, 510-8561, Japan. hiroshi-matsuura@mie-gmc.jp.

Shigeki Arase (S)

Department of Urology, Mie Prefectural General Medical Center, 5450-132 Hinaga, Yokkaichi, Mie, 510-8561, Japan.

Yasuhide Hori (Y)

Department of Urology, Mie Prefectural General Medical Center, 5450-132 Hinaga, Yokkaichi, Mie, 510-8561, Japan.
Department of Urology, Kameyama Nephro-Urological Clinic, 1488-215 Sakaemachi, Kameyama, Mie, 519-0111, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH